Follistatin 344 Peptide Dosing Guide: Optimal Protocols

Overview

Follistatin 344 is an isoform of follistatin (FST), a naturally occurring glycoprotein that binds and neutralizes members of the TGF-beta superfamily, most notably myostatin (GDF-8) and activin A. By inhibiting myostatin, follistatin 344 has drawn significant research attention for its potential role in muscle growth, tissue repair, and recovery. Animal studies have shown dramatic and in some cases permanent muscle hypertrophy with single gene therapy doses. However, human pharmacokinetic and safety data are extremely limited, and the compound is not FDA-approved for therapeutic use. This guide provides an educational overview of follistatin 344 dosing patterns discussed in research literature, presented as a text-based dosage chart for discussion with a licensed healthcare provider. You can use our Follistatin 344 dosage calculator → to plan protocol schedules and check reconstitution math — for educational purposes only.

What is follistatin 344?

Follistatin 344, also known as FST344 or myostatin inhibitor, is a peptide isoform of the naturally occurring follistatin protein. It works by binding to and neutralizing myostatin (GDF-8), a protein that normally limits muscle growth. When myostatin is inhibited, muscle cells can grow larger and multiply more readily. This mechanism has made follistatin 344 a subject of intense research interest in the fields of muscle wasting disorders, sarcopenia, and tissue repair. To calculate your protocol dosing, see our Follistatin 344 dosage calculator →

Key characteristics:

• Mechanism: Binds and neutralizes myostatin (GDF-8) and activin A
• Half-life: Approximately 35 hours
• Route: Subcutaneous injection (research context)
• Legal status: Not FDA-approved — research only, extreme caution advised
• Alternate names: FST344, myostatin inhibitor

Animal research has demonstrated that follistatin gene therapy can produce permanent muscle hypertrophy from a single dose. While these results are striking, they also highlight why human use outside of clinical supervision carries significant risk — the potential for irreversible muscular changes and unknown off-target effects.

Follistatin 344 dosage chart

There is no established safe human dose for follistatin 344. The chart below summarizes dosing patterns discussed in published research protocols and peptide community discussions. It is intended for educational reference only — not as a personal dosing plan or medical recommendation.

Protocol Phase	Dose Range	Frequency	Duration	Route	Use Case
Research loading	100-300 mcg per day	Daily	10-20 days	Subcutaneous injection	Initial research protocol, muscle growth focus
Extended research	100-200 mcg per day	Daily	20-30 days	Subcutaneous injection	Extended protocol for sustained myostatin inhibition
Lower-dose exploratory	50-100 mcg per day	Daily	10-15 days	Subcutaneous injection	Conservative starting approach, minimal exposure
Cycle break	No dose	N/A	4-8 weeks off	N/A	Recovery period between research cycles
Maintenance (if continued)	50-100 mcg per day	2-3x per week	Ongoing	Subcutaneous injection	Lower-frequency ongoing research

If you want to organize a protocol schedule or check reconstitution math, use our Follistatin 344 dosage calculator → — but only as a conversation tool, not a self-treatment plan. Important: These ranges are drawn from research community discussions, not FDA-approved clinical guidelines. No safe human dose has been established. Any use should be discussed with a licensed healthcare provider.

How follistatin 344 works in the body

Follistatin 344 functions as a myostatin inhibitor. Myostatin (GDF-8) is a member of the TGF-beta superfamily that acts as a negative regulator of muscle growth — it signals muscle cells to stop growing. By binding to myostatin and activin A, follistatin 344 prevents these signaling proteins from reaching their receptors, effectively removing the brake on muscle growth.

In animal models, this has resulted in:

• Significant increases in muscle mass (hypertrophy)
• Reduction in body fat percentage
• Improved muscle regeneration after injury
• In gene therapy models, permanent muscle changes from a single dose

The approximately 35-hour half-life means the compound remains active in the body for more than a day after injection, which is why most research protocols use daily rather than multiple daily injections.

Potential benefits discussed in research

Research on follistatin 344 often focuses on several areas:

1. Muscle growth and hypertrophy — the primary researched application, with animal studies showing dramatic muscle mass increases

2. Tissue repair and recovery — follistatin may support muscle regeneration after injury

3. Sarcopenia and muscle wasting — potential application in age-related or disease-related muscle loss

4. Metabolic effects — some research suggests improved body composition beyond muscle growth alone

However, it is critical to note that most evidence comes from animal studies. Human pharmacokinetic and safety data are extremely limited, and no therapeutic dose has been established for any human indication.

Safety considerations

The risk profile of follistatin 344 is not well characterized in humans. Key safety points include:

• Irreversible muscular hypertrophy — animal gene therapy studies show permanent muscle changes, which raises concerns about uncontrolled or unintended growth in humans
• Unknown off-target effects — because follistatin interacts with multiple TGF-beta family members beyond myostatin, effects on other tissues are possible but not well studied
• Injection site reactions — redness, pain, and irritation at the injection site are the most commonly reported side effects in research settings
• Mild nausea — reported in some research protocols
• No established monitoring protocol — unlike FDA-approved medications, there are no standardized lab tests or monitoring guidelines for follistatin 344 use

Before considering any follistatin 344 protocol, discuss with a healthcare provider:

• Complete medical history including muscle or neurological conditions
• Current medications and supplements
• Any history of injection site reactions
• Pregnancy or lactation status
• Liver and kidney function
• The exact product source, concentration, and labeling

Administration and reconstitution

In research contexts, follistatin 344 is typically administered via subcutaneous injection. Standard reconstitution uses bacteriostatic water.

Key administration notes:

• Reconstitute with bacteriostatic water according to product instructions
• Inject subcutaneously, typically in the abdomen or outer thigh
• Rotate injection sites daily to reduce local irritation
• After reconstitution, refrigerate and use within the timeframe specified by the product. For exact reconstitution math, use our Follistatin 344 dosage calculator →
• Inspect the solution before use — do not use if cloudy or containing particulate matter
• The approximately 35-hour half-life supports once-daily dosing in most research protocols

Common mistakes with follistatin 344 dosing

1. Treating research doses as therapeutic doses — there is no established safe human dose. Research community numbers are not clinical guidelines.

2. Assuming more is better — given the potential for irreversible muscle changes and unknown off-target effects, increasing dose outside medical guidance increases risk without evidence of additional benefit.

3. Stacking without medical supervision — combining follistatin 344 with other peptides (BPC-157, TB-500, IGF-1) may compound risks and make side effects harder to identify.

4. Ignoring cycle breaks — research protocols typically include off-periods. Continuous use without breaks increases the risk of cumulative effects that are not yet understood.

The practical takeaway

Follistatin 344 is a powerful myostatin inhibitor with remarkable animal research data, but it remains highly experimental in humans. No safe human dose has been established, and the compound is not FDA-approved for any therapeutic use. The dosing patterns in this guide are drawn from research community discussions, not clinical evidence.

For anyone considering follistatin 344, the responsible approach is to treat it as what it is — a research compound with significant potential and significant unknowns. Discuss any protocol with a qualified healthcare provider, understand the risks of irreversible effects, and use dosage charts as educational tools rather than personal prescriptions.

Related Peptides

Frequently Asked Questions

Related Guides